• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Seer Inc. (Amendment)

    2/14/23 4:21:25 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $SEER alert in real time by email
    SC 13G/A 1 tm236774d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    (Amendment No. 2)*

     

     

     

    SEER, INC.

    (Name of Issuer)

     

     

     

    Class A Common Stock, $0.00001 par value per share

    (Title of Class of Securities)

     

    81578P 106

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    ¨Rule 13d-1(c)
    xRule 13d-1(d)

     

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 81578P 106 Page 2

     

                 
    1   

    NAME OF REPORTING PERSON:

     

    Omid Farokhzad

       

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

     

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a)   ¨        

    (b)   ¨

    3  

    SEC USE ONLY:

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    United States 

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        5   

    SOLE VOTING POWER

     

    2,634,224 (1)(2)

        6  

    SHARED VOTING POWER

     

    3,420,616 (2)(3)

        7  

    SOLE DISPOSITIVE POWER

     

    2,634,224 (1)(2)

        8  

    SHARED DISPOSITIVE POWER

     

    3,420,616 (2)(3)

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    6,054,840 (1)(2)(3)

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):     ¨   

     

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

    9.4 (2)(4)(5)

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    IN

    (1) Consists of (i) 392,763 shares of Class A common stock and 134,579 shares of Class B common stock held of record by Omid Farokhzad (the “Reporting Person”); (ii) 2,035,222 shares of Class A common stock subject to options exercisable within 60 days of December 31, 2022 and (iii) 71,660 shares of Class A common stock issuable upon vesting of RSUs within 60 days of December 31, 2022.
    (2) Each share of Class B common stock is convertible at any time into one share of Class A common stock.
    (3) Consists of (i) 1,303,478 shares of Class B common stock held of record by Dynamics Group LLC for which the Reporting Person serves as the sole member and (ii) 2,117,138 shares of Class B common stock held of record by SAF-BND Trust for which the Reporting Person’s spouse serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by the SAF-BND Trust.
    (4) Based on the quotient obtained by dividing (a) the aggregate amount beneficially owned by the Reporting Person as set forth in Row 9 by (b) the sum of (i) 58,596,598 shares of Class A common stock outstanding as of November 4, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022, filed with the Securities and Exchange Commission on November 8, 2022 (the “Form 10-Q”); (ii) 3,555,195 shares of Class B common stock beneficially owned by the Reporting Person; (iii) 2,035,222 shares of Class A common stock subject to options exercisable within 60 days of December 31, 2022 and (iv) 71,660 shares of Class A common stock issuable upon vesting of RSUs within 60 days of December 31, 2022. The aggregate number of shares of Class B common stock beneficially owned by the Reporting Person as set forth in clause “(a)” of this footnote are treated as converted into Class A common stock only for the purpose of computing the percentage ownership of the Reporting Person.
    (5) Each share of Class A common stock is entitled to one vote and each share of Class B common stock is entitled to ten votes. The percentage reported does not reflect the ten for one voting power of the Class B common stock because these shares are treated as converted into Class A common stock for the purpose of this report.

     

     

     

     

    Item 1

     

    (a)Name of Issuer:

     

    Seer, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices:

     

    3800 Bridge Parkway, Suite 102

    Redwood City, California 94065

     

    Item 2

     

    (a)Name of Person Filing:

     

    Omid Farokhzad

     

    (b)Address or principal business office or, if none, residence:

     

    The address for the principal business office of Dr. Farokhzad is:

     

    c/o Seer, Inc.

    3800 Bridge Parkway, Suite 102

    Redwood City, California 94065

     

    (c)Citizenship:

     

    United States

     

    (d)Title and Class of Securities:

     

    Class A common stock, par value, $0.00001 per share.

     

    (e)CUSIP No.:

     

    81578P 106

     

    Item 3.If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4.Ownership

     

    (a)Amount beneficially owned: 6,054,840

     

    (b)Percent of class: 9.4

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to direct the vote: 2,634,224 (1)(2)

     

    (ii)Shared power to direct the vote: 3,420,616 (2)(3)

     

    (iii)Sole power to dispose or to direct the disposition of: 2,634,224 (1)(2)

     

    (iv)Shared power to dispose or to direct the disposition of: 3,420,616 (2)(3)

     

    (1) Consists of (i) 392,763 shares of Class A common stock and 134,579 shares of Class B common stock held of record by Omid Farokhzad (the “Reporting Person”); (ii) 2,035,222 shares of Class A common stock subject to options exercisable within 60 days of December 31, 2022 and (iii) 71,660 shares of Class A common stock issuable upon vesting of RSUs within 60 days of December 31, 2022.

     

    (2) Each share of Class B common stock is convertible at any time into one share of Class A common stock.

     

    (3) Consists of (i) 1,303,478 shares of Class B common stock held of record by Dynamics Group LLC for which the Reporting Person serves as the sole member and (ii) 2,117,138 shares of Class B common stock held of record by SAF-BND Trust for which the Reporting Person’s spouse serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by the SAF-BND Trust.

     

     

     

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    Not applicable.

     

    Item 6.Ownership of More than 5 Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7.          Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certifications

     

    Not applicable.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2023  
       
      /s/ Omid Farokhzad
      Omid Farokhzad

     

     

     

    Get the next $SEER alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SEER

    DatePrice TargetRatingAnalyst
    5/4/2026$4.00Buy
    Canaccord Genuity
    7/5/2023$10.00Neutral
    JP Morgan
    1/4/2023$9.00 → $6.50Neutral → Underperform
    BofA Securities
    8/11/2022$20.00 → $12.00Overweight → Neutral
    JP Morgan
    3/1/2022$23.00 → $21.00Equal-Weight
    Morgan Stanley
    2/15/2022$46.00 → $23.00Equal-Weight
    Morgan Stanley
    10/15/2021Outperform
    Cowen
    8/13/2021$55.00 → $50.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SEER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Seer with a new price target

    Canaccord Genuity initiated coverage of Seer with a rating of Buy and set a new price target of $4.00

    5/4/26 8:35:45 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    JP Morgan resumed coverage on Seer with a new price target

    JP Morgan resumed coverage of Seer with a rating of Neutral and set a new price target of $10.00

    7/5/23 7:25:16 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer downgraded by BofA Securities with a new price target

    BofA Securities downgraded Seer from Neutral to Underperform and set a new price target of $6.50 from $9.00 previously

    1/4/23 9:03:59 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Seer Urges Stockholders to Vote “FOR” Seer’s Highly Qualified Director Nominees on the BLUE Proxy Card TODAY

    2026 Annual Meeting of Stockholders To Be Held July 28, 2026 Seer’s Board of Directors is Highly Engaged, Independent and Purpose-Built to Oversee Strategic Execution at This Critical Time Radoff-JEC Group’s Nominees Lack Qualifications, Expertise and Independence Necessary to Add Value to Board REDWOOD CITY, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company") today issued a letter to stockholders reminding them to vote their shares ahead of the Company’s upcoming 2026 Annual Meeting of Stockholders (the "Annual Meeting"), scheduled to be held on July 28, 2026 at 1:30 p.m. Pacific Time. Stockholders as of May 29, 2026 are entitled to vote at the

    7/20/26 7:00:00 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Special Committee of Seer’s Board of Directors Unanimously Rejects Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.

    REDWOOD CITY, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the Special Committee of Seer’s Board of Directors, consisting of independent directors Meeta Gulyani and Nicolas Roelofs, Ph.D., has thoroughly reviewed and unanimously rejected the unsolicited, non-binding proposal received on July 1, 2026, from Omid Farokhzad, M.D., Seer’s Chair and Chief Executive Officer, to acquire all of the outstanding shares of Seer’s Class A common stock for $2.45 per share in cash plus two separate contingent value rights (the "Proposal"). Consistent with its fiduciary duties, the Special C

    7/20/26 6:00:00 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Radoff-JEC Group Announces ISS’ Support of its Case for Change at Seer, Inc.

    ISS Recommends Stockholders Vote FOR Radoff-JEC Group Nominees Howard H. Berman and Luis E. Rinaldini, WITHHOLD Support on Seer Directors Terrance McGuire, Dipchand Nishar and Nicolas Roelofs and Vote AGAINST the NOL Pill Concludes That the Board’s Actions "[Raise] Questions About the Ability of the Board to Exercise Independent Oversight" of Chairman and CEO Omid Farokhzad, M.D. Radoff-JEC Group Urges Stockholders to Vote on the WHITE Proxy Card to Elect All Three of its Independent, Qualified Nominees Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group" or "we"), who collectively own approximately 7.7% of Seer, Inc.’s (NASDAQ:SEER) (

    7/17/26 8:20:00 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    SEC Filings

    View All

    SEC Form DEFA14A filed by Seer Inc.

    DEFA14A - Seer, Inc. (0001726445) (Filer)

    7/20/26 4:10:47 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 8-K filed by Seer Inc.

    8-K - Seer, Inc. (0001726445) (Filer)

    7/20/26 4:08:49 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DEFA14A filed by Seer Inc.

    DEFA14A - Seer, Inc. (0001726445) (Filer)

    7/20/26 8:03:56 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Nishar Dipchand sold $23,265 worth of shares (10,660 units at $2.18) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 59,044 units (SEC Form 4) to cover withholding tax

    4 - Seer, Inc. (0001726445) (Issuer)

    7/10/26 6:23:12 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PRESIDENT & CFO Horn David R. sold $12,352 worth of shares (7,303 units at $1.69), decreasing direct ownership by 1% to 493,959 units (SEC Form 4) (tax liability)

    4 - Seer, Inc. (0001726445) (Issuer)

    5/21/26 5:12:54 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Commercial Officer Bazarko Anthony R. was granted 75,000 shares (SEC Form 4)

    4 - Seer, Inc. (0001726445) (Issuer)

    5/11/26 6:20:12 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Financials

    Live finance-specific insights

    View All

    Seer Board of Directors Issues Letter to Shareholders Highlighting the Company's Significant Scientific Progress and Addressing Radoff and Torok's Short-Sighted Campaign

    REDWOOD CITY, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company") today issued a letter to stockholders containing important information for shareholders to consider in connection with the Company's upcoming Annual Meeting of Stockholders (the "Annual Meeting") to be held on July 28, 2026. Stockholders as of May 29, 2026 will be entitled to vote at the Annual Meeting. The Board recommends that stockholders vote "FOR" the election of Seer's seven highly qualified nominees on the BLUE proxy card. The full text of the letter follows: Dear Fellow Seer Stockholders, You have an important choice to make regarding the future of Seer at our upcoming Ann

    6/15/26 7:00:00 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Files Definitive Proxy Materials and Mails Letter to Stockholders

    Reinforces Seer's Clear Strategy, Strong Governance and Significant Long-Term Value Creation Opportunity Illustrates Why Radoff and Torok's Short-Term Campaign Risks Disrupting Seer's Momentum and Undermines Stockholder Value Urges Stockholders to Vote "FOR" ONLY Seer's Director Nominees on the BLUE Proxy Card REDWOOD CITY, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company"), today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the Company's upcoming Annual Meeting of Stockholders (the "Annual Meeting") to be held on July 28, 2026. Stockholders of record as of

    6/3/26 6:00:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Reports First Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook

    REDWOOD CITY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER) ("Seer" or the "Company"), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial results for the quarter ended March 31, 2026. Recent Highlights Achieved revenue of $2.8 million in the first quarter of 2026Achieved a doubling of independent publications year-over-year to 84 total, accelerating third-party validation of Seer's platformSecured a collaboration with Precision Health Research, Singapore to provide deep, unbiased proteomics on 10,000 samples for their PRECISE-SG100K study, a landmark multi-ancestry, population-scale cohort of approximately 100,000 Singapo

    5/13/26 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Seer Inc.

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    8/2/24 6:33:25 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Seer Inc.

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    7/8/24 4:32:39 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Seer Inc. (Amendment)

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    4/10/24 10:06:09 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Leadership Updates

    Live Leadership Updates

    View All

    Seer Announces Appointment of Anthony Bazarko as Chief Commercial Officer

    Seasoned life sciences executive brings extensive global commercial leadership to accelerate growth and expand adoption of Seer's Proteograph® Product Suite REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a pioneer and trusted partner for deep, unbiased proteomic insights, today announced the appointment of Anthony Bazarko as Chief Commercial Officer. Mr. Bazarko brings more than two decades of commercial leadership experience across the life sciences, diagnostics, and biotechnology industries, with a demonstrated track record of driving revenue growth, building high-performing teams, and leading global go-to-market strategies. Mr. Bazarko joins Seer from

    5/4/26 7:00:00 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Appoints Isaac Ro to its Board of Directors

    REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to serve on its Board of Directors. "We are excited to welcome Isaac to our board," said Omid Farokhzad, Chair and CEO of Seer. "Isaac brings a rare combination of financial leadership and deep sector experience across life science tools, diagnostics, and the broader healthcare ecosystem. His proven track record of guiding companies through transformative growth will be invaluable as we continue to execute on key milestones and accelerate the impact of our platform." "I'm looking forward to work

    9/2/25 7:00:00 AM ET
    $SEER
    $WGS
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Retail: Computer Software & Peripheral Equipment
    Technology

    Seer Appoints Nicolas Roelofs to its Board of Directors

    REDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Dr. Nicolas Roelofs to serve on its Board of Directors. "Nick is a fantastic addition to our board, bringing over 35 years of broad operational and advisory experience with leading healthcare, life science tools, and diagnostics companies," said Omid Farokhzad, Chair and CEO of Seer. "His extensive experience and insights will be valuable as we advance our mission of opening up a new gateway to the proteome." "I'm excited to work with the Seer team and leverage my experience in the life

    8/14/24 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials